An expanded access record providing Mitomycin for pyelocalyceal solution in Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter and Urothelial Carcinoma Ureter, sponsored by UroGen Pharma Ltd.. Available. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by UroGen Pharma Ltd. · Expanded access
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Carcinoma, Transitional Cell by UroGen Pharma Ltd. — 2 open to participants now, 3 under way, 2 of them phase 3. Carcinoma, Transitional Cell · UroGen Pharma Ltd..
Among the 10 studies in Carcinoma, Transitional Cell by UroGen Pharma Ltd., this one is the only one of another kind, and was the 7th registered.
633 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.
Browse Carcinoma, Transitional Cell studies →2 of the 10 studies in Carcinoma, Transitional Cell by UroGen Pharma Ltd. are open now, in 9 countries. Recruiting first, the newest first:
UroGen Pharma Ltd. · Sites in United States, Bulgaria, Georgia and 6 more countries
Ages 18+
UroGen Pharma Ltd. · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 71 across the 8 interventional studies, 450 across the 1 observational. Of the 5 that completed or were terminated, 5 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
UroGen Pharma Ltd. is the lead sponsor of 19 studies on the registry; 3 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
2 of the studies in Carcinoma, Transitional Cell by UroGen Pharma Ltd. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06774131Phase 3UroGen Pharma Ltd.A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer | 2027-03 |
| NCT05874921UroGen Pharma Ltd.uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto | 2027-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Carcinoma, Transitional Cell by UroGen Pharma Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
This program provides controlled, pre-approval access to JELMYTO in response to unsolicited requests by physicians, hospitals, pharmacies, distributors, ministries of health or other parties on behalf of specific, or named patients, in select countries where JELMYTO has not yet received a marketing authorization and in situations when patients have exhausted all available treatment options.
Inclusion Criteria:
Also known as: JELMYTO
No study locations are listed for this record.
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
Contact the providerGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Transitional Cell →
UroGen Pharma Ltd.